23
Participants
Start Date
October 31, 2008
Primary Completion Date
May 31, 2011
Study Completion Date
October 31, 2011
BIW-8962
Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
Duke Medical Center, Durham
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Taussig Cancer Center- Cleveland Clinic, Cleveland
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Karmanos Cancer Institute, Detroit
Collaborators (1)
Kyowa Hakko Kirin Pharma, Inc.
INDUSTRY
Kyowa Kirin Co., Ltd.
INDUSTRY